MedDataX Logo

Effect of the Intensity of Continuous Renal Replacement Therapy

NCT ID: NCT01251081

Last Updated: 2010-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

280 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-01-31

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients with sepsis and AKI, increasing the intensity of renal replacement therapy from 50 mL/kg/h (HVHF) to 85 mL/kg/h (EHVHF)will increase the survival at 28 days and 90 days.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Optimal Intensity of Renal Replacement Therapy on Sepsis Patients

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

high volume hemofiltration sepsis acute kidney injury survival

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

extra high volume hemofiltration

extra high volume hemofiltration (85 mL/kg/h, EHVHF)

Group Type EXPERIMENTAL

extra high volume hemofiltration

Intervention Type OTHER

extra high volume hemofiltration (85 mL/kg/h, EHVHF)

high volume hemofiltration

high volume hemofiltration (50 mL/kg/h, HVHF)

Group Type SHAM_COMPARATOR

high volume hemofiltration

Intervention Type OTHER

high volume hemofiltration (50 mL/kg/h, HVHF)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

extra high volume hemofiltration

extra high volume hemofiltration (85 mL/kg/h, EHVHF)

Intervention Type OTHER

high volume hemofiltration

high volume hemofiltration (50 mL/kg/h, HVHF)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

met at least one of the following criteria: oliguria (urine output less than 100 mL in a 6 h period and unresponsive to fluid resuscitation), serum potassium concentration more than 6.5 mmol/L, severe acidemia (pH \< 7.2), serum creatinine more than 250 µmol/L, or presence of severe organ edema (e.g. pulmonary edema).

Exclusion Criteria

* were presence of a malignant tumor, chronic renal insufficiency (serum creatinine \>133 µmol/L), or receiving any kind of renal replacement therapy before randomization.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zhejiang University

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

jianghua chen, MD

Role: STUDY_DIRECTOR

Kidney disease center, the first affiliated hospital, medical college of Zhejiang university

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kidney disease center, the first affiliated hospital, medical college of Zhejiang university

Hangzhou, Zhejiang, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VHVHF

Identifier Type: -

Identifier Source: org_study_id